Literature DB >> 25139989

Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors.

Robert W Tell1, Curt M Horvath2.   

Abstract

Signal transducer and activator of transcription 3 (STAT3), a latent transcription factor associated with inflammatory signaling and innate and adaptive immune responses, is known to be aberrantly activated in a wide variety of cancers. In vitro analysis of STAT3 in human cancer cell lines has elucidated a number of specific targets associated with poor prognosis in breast cancer. However, to date, no comparison of cancer subtype and gene expression associated with STAT3 signaling in human patients has been reported. In silico analysis of human breast cancer microarray and reverse-phase protein array data was performed to identify expression patterns associated with STAT3 in basal-like and luminal breast cancers. Results indicate clearly identifiable STAT3-regulated signatures common to basal-like breast cancers but not to luminal A or luminal B cancers. Furthermore, these differentially expressed genes are associated with immune signaling and inflammation, a known phenotype of basal-like cancers. These findings demonstrate a distinct role for STAT3 signaling in basal breast cancers, and underscore the importance of considering subtype-specific molecular pathways that contribute to tissue-specific cancers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25139989      PMCID: PMC4156751          DOI: 10.1073/pnas.1404881111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Authors:  Chad A Livasy; Gamze Karaca; Rita Nanda; Maria S Tretiakova; Olufunmilayo I Olopade; Dominic T Moore; Charles M Perou
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

3.  miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells.

Authors:  Sandra Cascio; Aleco D'Andrea; Rita Ferla; Eva Surmacz; Eliana Gulotta; Valeria Amodeo; Viviana Bazan; Nicola Gebbia; Antonio Russo
Journal:  J Cell Physiol       Date:  2010-07       Impact factor: 6.384

4.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Authors:  Michael Hedvat; Dennis Huszar; Andreas Herrmann; Joseph M Gozgit; Anne Schroeder; Adam Sheehy; Ralf Buettner; David Proia; Claudia M Kowolik; Hong Xin; Brian Armstrong; Geraldine Bebernitz; Shaobu Weng; Lin Wang; Minwei Ye; Kristen McEachern; Huawei Chen; Deborah Morosini; Kirsten Bell; Marat Alimzhanov; Stephanos Ioannidis; Patricia McCoon; Zhu A Cao; Hua Yu; Richard Jove; Michael Zinda
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

5.  Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines.

Authors:  Ju-Hwa Kim; Seok Chul Lee; Jungsil Ro; Han Sung Kang; Hyung Sik Kim; Sungpil Yoon
Journal:  Biochem Pharmacol       Date:  2009-09-18       Impact factor: 5.858

Review 6.  The emerging role of immunosurveillance in dictating metastatic spread in breast cancer.

Authors:  Clare Y Slaney; Jai Rautela; Belinda S Parker
Journal:  Cancer Res       Date:  2013-09-23       Impact factor: 12.701

7.  Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer.

Authors:  Yuh Baba; Masato Fujii; Yutaka Tokumaru; Yasumasa Kato
Journal:  J Oncol       Date:  2012-03-26       Impact factor: 4.375

8.  STAT3 or USF2 contributes to HIF target gene specificity.

Authors:  Matthew R Pawlus; Liyi Wang; Aya Murakami; Guanhai Dai; Cheng-Jun Hu
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

9.  Differential expression analysis for sequence count data.

Authors:  Simon Anders; Wolfgang Huber
Journal:  Genome Biol       Date:  2010-10-27       Impact factor: 13.583

10.  miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer.

Authors:  Michael S Hwang; Nancy Yu; Susanna Y Stinson; Peng Yue; Robert J Newman; Bernard B Allan; David Dornan
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

View more
  27 in total

1.  QuantFusion: Novel Unified Methodology for Enhanced Coverage and Precision in Quantifying Global Proteomic Changes in Whole Tissues.

Authors:  Harsha P Gunawardena; Jonathon O'Brien; John A Wrobel; Ling Xie; Sherri R Davies; Shunqiang Li; Matthew J Ellis; Bahjat F Qaqish; Xian Chen
Journal:  Mol Cell Proteomics       Date:  2015-11-23       Impact factor: 5.911

2.  p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.

Authors:  Amir Sonnenblick; Roberto Salgado; Sylvain Brohée; Tamar Zahavi; Tamar Peretz; Gert Van den Eynden; Ghizlane Rouas; Asher Salmon; Prudence A Francis; Angelo Di Leo; John P A Crown; Giuseppe Viale; Laura Daly; Bahar Javdan; Sho Fujisawa; Evandro De Azambuja; Ameye Lieveke; Martine J Piccart; Jacqueline F Bromberg; Christos Sotiriou
Journal:  Int J Oncol       Date:  2017-11-27       Impact factor: 5.650

Review 3.  Reverse phase protein arrays: mapping the path towards personalized medicine.

Authors:  Rosa I Gallagher; Virginia Espina
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

4.  ADAM12 Is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling.

Authors:  Roopali Roy; Adelle Dagher; Catherine Butterfield; Marsha A Moses
Journal:  Mol Cancer Res       Date:  2017-08-01       Impact factor: 5.852

Review 5.  Constitutive activation of STAT3 in breast cancer cells: A review.

Authors:  Kasturi Banerjee; Haluk Resat
Journal:  Int J Cancer       Date:  2015-11-28       Impact factor: 7.396

6.  STAT3 induces breast cancer growth via ANGPTL4, MMP13 and STC1 secretion by cancer associated fibroblasts.

Authors:  Lidia Avalle; Laura Raggi; Emanuele Monteleone; Aurora Savino; Daniele Viavattene; Luisa Statello; Andrea Camperi; Simona Aversano Stabile; Vincenzo Salemme; Niccolò De Marzo; Francesca Marino; Chiara Guglielmi; Andrea Lobascio; Cristina Zanini; Marco Forni; Danny Incarnato; Paola Defilippi; Salvatore Oliviero; Valeria Poli
Journal:  Oncogene       Date:  2022-01-18       Impact factor: 8.756

7.  Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.

Authors:  Chun-Yu Liu; Kuen-Feng Chen; Tzu-I Chao; Pei-Yi Chu; Chun-Teng Huang; Tzu-Ting Huang; Hsiu-Ping Yang; Wan-Lun Wang; Chia-Han Lee; Ka-Yi Lau; Wen-Chun Tsai; Jung-Chen Su; Chia-Yun Wu; Ming-Huang Chen; Chung-Wai Shiau; Ling-Ming Tseng
Journal:  J Mol Med (Berl)       Date:  2017-06-04       Impact factor: 4.599

8.  Identification of a Novel Transcription Factor Prognostic Index for Breast Cancer.

Authors:  Junhao Liu; Zexuan Liu; Yangying Zhou; Manting Zeng; Sanshui Pan; Huan Liu; Qiong Liu; Hong Zhu
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

9.  Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.

Authors:  Amir Sonnenblick; Sylvain Brohée; Debora Fumagalli; Delphine Vincent; David Venet; Michail Ignatiadis; Roberto Salgado; Gert Van den Eynden; Françoise Rothé; Christine Desmedt; Patrick Neven; Sibylle Loibl; Carsten Denkert; Heikki Joensuu; Sherene Loi; Nicolas Sirtaine; Pirkko-Liisa Kellokumpu-Lehtinen; Martine Piccart; Christos Sotiriou
Journal:  BMC Med       Date:  2015-08-03       Impact factor: 8.775

10.  STAT3 localizes to the ER, acting as a gatekeeper for ER-mitochondrion Ca2+ fluxes and apoptotic responses.

Authors:  Lidia Avalle; Annalisa Camporeale; Giampaolo Morciano; Natascia Caroccia; Elena Ghetti; Valeria Orecchia; Daniele Viavattene; Carlotta Giorgi; Paolo Pinton; Valeria Poli
Journal:  Cell Death Differ       Date:  2018-07-24       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.